248 related articles for article (PubMed ID: 231736)
1. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
Sallan SE; Cronin C; Zelen M; Zinberg NE
N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
[TBL] [Abstract][Full Text] [Related]
3. Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy.
Drug Ther Bull; 1984 Feb; 22(3):9-11. PubMed ID: 6321126
[No Abstract] [Full Text] [Related]
4. Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy.
Ungerleider JT; Andrysiak TA; Fairbanks LA; Tesler AS; Parker RG
Radiology; 1984 Feb; 150(2):598-9. PubMed ID: 6318262
[TBL] [Abstract][Full Text] [Related]
5. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED
N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.
Bishop JF; Wolf M; Matthews JP; Scott K; Ackland S; Yuen K; Morton C; Hillcoat BL; Cooper IA
Cancer Treat Rep; 1987 Nov; 71(11):1007-11. PubMed ID: 3315193
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy.
Winokur SH; Baker JJ; Lokey JL; Price NA; Bowen J
J Med Assoc Ga; 1981 Apr; 70(4):263-4. PubMed ID: 7012258
[No Abstract] [Full Text] [Related]
9. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
Chan HS; Correia JA; MacLeod SM
Pediatrics; 1987 Jun; 79(6):946-52. PubMed ID: 3035479
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Aapro MS
Ariz Med; 1981 Nov; 38(11):843-5. PubMed ID: 6274276
[No Abstract] [Full Text] [Related]
11. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
12. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
Colls BM; Ferry DG; Gray AJ; Harvey VJ; McQueen EG
N Z Med J; 1980 Jun; 91(662):449-51. PubMed ID: 6250106
[TBL] [Abstract][Full Text] [Related]
13. Anticipatory nausea and vomiting associated with cancer chemotherapy.
Weddington WW; Miller NJ; Sweet DL
N Engl J Med; 1982 Sep; 307(13):825-6. PubMed ID: 6287263
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
15. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
Osoba D; Erlichman C; Willan AR; Levitt M; Pater JL
Clin Invest Med; 1986 Nov; 9(4):225-31. PubMed ID: 3542325
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.
Steele N; Gralla RJ; Braun DW; Young CW
Cancer Treat Rep; 1980; 64(2-3):219-24. PubMed ID: 6250699
[TBL] [Abstract][Full Text] [Related]
17. [Vomiting accompanying cytostatic treatment, and its control].
Kotlarek-Haus S; Orzechowska-Juzwenko K; Gabryś K
Pol Tyg Lek; 1984 Nov; 39(47):1555-9. PubMed ID: 6151174
[No Abstract] [Full Text] [Related]
18. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
Herman TS; Einhorn LH; Jones SE; Nagy C; Chester AB; Dean JC; Furnas B; Williams SD; Leigh SA; Dorr RT; Moon TE
N Engl J Med; 1979 Jun; 300(23):1295-7. PubMed ID: 375088
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
Sallan SE; Zinberg NE; Frei E
N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
[TBL] [Abstract][Full Text] [Related]
20. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
